secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001437749-25-024955
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart receives stop work order from BARDA on Phase 2b oral COVID-19 vaccine trial
--------------------------------------------------------------------------------

- ATI/BARDA directed Vaxart to stop all work on Project Agreement RRPV-24-04-NGVx-003 for oral COVID-19 vaccine.
- Company may only continue follow-up for already dosed participants in the 10,000-person cohort; enrollment about half complete.
- No reason provided; DSMB had determined on July 14 that the study could proceed without modification.
- Company expects a follow-up notice with further details; no additional funding or termination decision announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774925024955/0001437749-25-024955-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774925024955/vxrt20250805_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-024955

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer